New combo aims to turn inoperable liver cancer into surgical candidates
NCT ID NCT07179900
First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 26 times
Summary
This study tests whether adding radiotherapy to a standard immunotherapy-plus-bevacizumab regimen can shrink liver tumors enough to allow surgery. Sixty adults with unresectable, non-spreading liver cancer will be randomly assigned to receive either the triple combination or the standard two-drug therapy. The main goals are to see how many patients' tumors shrink or become surgically removable, and to monitor side effects and long-term outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.